The prevalence of psychotic symptoms in kratom (Mitragyna speciosa Korth.) Users in Malaysia

Asian J Psychiatr. 2019 Jun:43:197-201. doi: 10.1016/j.ajp.2019.07.008. Epub 2019 Jul 5.

Abstract

Background: Kratom is a traditional medicinal herb widely used in Malaysia and Thailand. Despite its widespread use and statements by regulatory agencies on the potential for kratom-associated psychosis, there is little data regarding the prevalence of psychotic symptoms among kratom users. This study investigated the prevalence of psychosis among kratom users, described psychotic symptomatology and severity, while examining associations between kratom use characteristics and the occurrence of psychotic symptoms.

Methods: This cross-sectional clinical survey recruited 150 regular kratom users. The Mini International Neuropsychiatric Interview (MINI) and Diagnostic and Statistical Manual of Mental Disorders 5th Edition (DSM-V) diagnostic criteria were used to evaluate psychotic symptomatology among kratom users, and the Brief Psychiatric Rating Scale (BPRS) was used to assess the severity of psychiatric symptoms. Chi-square tests with Yate's correction were performed to determine the association between kratom use characteristics and the occurrence of psychotic symptoms among kratom users in this study.

Results: Six out of 150 kratom users (4%) presented with any psychotic symptoms. The psychotic symptoms reported were positive symptoms and thought alienation, with a mean BPRS score of 33 (i.e., mild severity). Variables related to kratom use (such as intake of kratom with diphenhydramine, duration of kratom use, and quantity and frequency of daily kratom use) were not associated with the occurrence of psychotic symptoms among kratom users.

Conclusion: Although psychotic symptoms could occur among regular kratom users, they were rare and not significantly associated with kratom use characteristics. We found no evidence of elevated psychosis among regular users.

Keywords: Kratom use; Malaysian kratom users; Psychosis; Psychotic symptoms severity.

MeSH terms

  • Adult
  • Cross-Sectional Studies
  • Female
  • Humans
  • Malaysia / epidemiology
  • Male
  • Middle Aged
  • Mitragyna / adverse effects*
  • Prevalence
  • Psychoses, Substance-Induced / epidemiology*
  • Psychoses, Substance-Induced / etiology*
  • Psychoses, Substance-Induced / physiopathology*
  • Severity of Illness Index